跳到正文
WHO 药品预认证与检查动态·· 6 天前AI 评分49

WHO 原料药预认证:浙江海正药业吡嗪酰胺通过预认证

Active Pharmaceutical Ingredient (API) Prequalified

AI 导读

浙江海正药业生产的吡嗪酰胺已通过 WHO 药品预认证团队的原料药预认证程序。该预认证包括原料药主文件(APIMF)评估和原料药生产场地 GMP 检查两部分。含吡嗪酰胺的制剂用于结核病治疗领域。

正文 · 原文

News

17 November, 2026 - 00:12 (CET)

Announcement

Pyrazinamide manufactured by Zhejiang Haizhou Pharmaceutical Co., Ltd. has been prequalified by the WHO Prequalification Team medicines under its API prequalification procedure.

Good-quality APIs are vital to the production of good-quality medicines.  WHO prequalification of APIs facilitates production of quality medicines by identifying such APIs for use by manufacturers of finished pharmaceutical products (FPPs). FPPs containing pyrazinamide are used in the therapeutic area of Tuberculosis.

API prequalification consists of a comprehensive evaluation procedure that has two components: assessment of the API master file (APIMF) to verify compliance with WHO norms and standards, and evaluation of the sites of API manufacture to verify compliance with WHO Good Manufacturing Practice requirements.

Links

来源:WHO 药品预认证与检查动态 · extranet.who.int